Innoviva EPS - Earnings per Share 2010-2023 | INVA
Innoviva eps - earnings per share from 2010 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Innoviva Annual EPS |
| 2023 |
$2.20 |
| 2022 |
$2.37 |
| 2021 |
$2.87 |
| 2020 |
$2.02 |
| 2019 |
$1.43 |
| 2018 |
$3.53 |
| 2017 |
$1.17 |
| 2016 |
$0.53 |
| 2015 |
$-0.16 |
| 2014 |
$-1.50 |
| 2013 |
$-1.67 |
| 2012 |
$-0.20 |
| 2011 |
$-1.41 |
| 2010 |
$-1.16 |
| 2009 |
$-1.35 |
| Innoviva Quarterly EPS |
| 2023-12-31 |
$0.78 |
| 2023-09-30 |
$0.98 |
| 2023-06-30 |
$0.02 |
| 2023-03-31 |
$0.42 |
| 2022-12-31 |
$-0.64 |
| 2022-09-30 |
$2.80 |
| 2022-06-30 |
$0.01 |
| 2022-03-31 |
$0.20 |
| 2021-12-31 |
$0.23 |
| 2021-09-30 |
$0.90 |
| 2021-06-30 |
$0.90 |
| 2021-03-31 |
$0.84 |
| 2020-12-31 |
$0.48 |
| 2020-09-30 |
$0.26 |
| 2020-06-30 |
$0.69 |
| 2020-03-31 |
$0.59 |
| 2019-12-31 |
$0.42 |
| 2019-09-30 |
$0.36 |
| 2019-06-30 |
$0.34 |
| 2019-03-31 |
$0.31 |
| 2018-12-31 |
$2.34 |
| 2018-09-30 |
$0.43 |
| 2018-06-30 |
$0.49 |
| 2018-03-31 |
$0.27 |
| 2017-12-31 |
$0.51 |
| 2017-09-30 |
$0.21 |
| 2017-06-30 |
$0.30 |
| 2017-03-31 |
$0.15 |
| 2016-12-31 |
$0.23 |
| 2016-09-30 |
$0.13 |
| 2016-06-30 |
$0.13 |
| 2016-03-31 |
$0.04 |
| 2015-12-31 |
$0.04 |
| 2015-09-30 |
$-0.04 |
| 2015-06-30 |
$-0.07 |
| 2015-03-31 |
$-0.09 |
| 2014-12-31 |
$-0.12 |
| 2014-09-30 |
$-0.19 |
| 2014-06-30 |
$-0.57 |
| 2014-03-31 |
$-0.62 |
| 2013-12-31 |
$-0.47 |
| 2013-09-30 |
$-0.44 |
| 2013-06-30 |
$-0.37 |
| 2013-03-31 |
$-0.39 |
| 2012-12-31 |
$-0.33 |
| 2012-09-30 |
$-0.37 |
| 2012-06-30 |
$-0.42 |
| 2012-03-31 |
$0.93 |
| 2011-12-31 |
$-0.45 |
| 2011-09-30 |
$-0.37 |
| 2011-06-30 |
$-0.31 |
| 2011-03-31 |
$-0.28 |
| 2010-12-31 |
$-0.24 |
| 2010-09-30 |
$-0.29 |
| 2010-06-30 |
$-0.28 |
| 2010-03-31 |
$-0.35 |
| 2009-12-31 |
$-0.34 |
| 2009-09-30 |
$-0.35 |
| 2009-06-30 |
$-0.35 |
| 2009-03-31 |
$-0.31 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.965B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
